The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →If funding for an HIV study is delayed, first establish exactly what is delayed: a new award, a continuation action, a payment, or another decision affecting an active award. Then review near-term participant-safety obligations and study costs with the PI, institutional grants office, IRB, and relevant study monitor before changing visits or research procedures. A funding delay is not, by itself, authorization to pause or alter a study.
Identify the funding event before making a continuity plan
Ask the institution’s sponsored-research or grants office to identify the delayed action in writing and explain its status under the award. A pending new award, a delayed continuation, and a late payment may have different consequences. The available NIH guidance does not establish that these situations share the same rules, nor does it make a funding delay equivalent to an award termination or a lapse in study authorization.
Have grants staff review the Notice of Award, current award terms, relevant NIH notices, and any institutional requirements. NIH maintains a dated index of policy notices; use the notice applicable to the circumstances rather than assuming an older emergency flexibility or a generic extension still applies: NIH Guide Notices.
As an Amazon Associate I earn from qualifying purchases.
Map the next operational deadlines
Study leadership and grants staff should make a short-term plan based on what participants and the study need next, not just the expected date of a payment. List:
- Upcoming participant visits, procedures, and follow-up windows, including any commitments already made to participants.
- Safety monitoring, adverse-event reporting, and other required reporting deadlines.
- Personnel, site, and essential laboratory costs needed to meet the approved protocol and protect participants.
- Study-monitor, collaborator, and vendor commitments that could affect continuity or data integrity.
Use this review to identify which obligations need a decision now and which costs might be affected if funds do not arrive on the anticipated schedule. Do not treat this practical planning list as a substitute for the award’s terms or the institution’s required review.
#1 Best Overall
Preserve participant protections and oversight
NIH states: “Once awarded, an institution must continually monitor the studies for adequate human subjects protections.” NIH also says: “NIH-defined clinical trials are required to provide a Data and Safety Monitoring Plan (DSMP) with the application or proposal.” The study team should keep required safety oversight and reporting routes functioning while the funding issue is assessed. NIH’s Post Award Human Subject Activities guidance also says: “Reportable events must be reported promptly.” Follow the applicable policies and timelines for the study; do not defer reportable events because funding is uncertain.
Bring the IRB and the study’s applicable data and safety monitoring body into the discussion before implementing a change that could affect participants or oversight. NIH guidance states: “In general, any change in research procedures in an active award that would result in an increased risk to human participants requires prior NIH approval before implementation.” NIH also identifies some human-subjects changes to an active award, including changes in scope or those that increase participant risk, as requiring prior approval. Confirm the specific approval route with institutional grants staff and the awarding institute before acting: NIH post-award guidance.
Recommended Free Tools
Do not assume visits can be paused or changed
Whether visits may be rescheduled, study activities reduced, or enrollment altered depends on the approved protocol, participant-safety considerations, IRB requirements, award terms, and any required NIH approval. Ask the PI and study leadership to propose options; have the IRB and relevant monitor assess participant implications, while the grants office checks award and approval requirements. Do not change procedures, participant populations, study scope, or the risk profile on the assumption that a funding delay itself authorizes the change.
If a proposed adjustment is necessary, document who reviewed it, which approvals or notifications are required, and when it may take effect. Continue the currently approved safety monitoring and reporting obligations unless the appropriate authorities confirm a change.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Check any bridge or budget option against the award
There is no universal bridge-funding, rebudgeting, carryover, or schedule-adjustment rule that resolves every NIH funding delay. Ask institutional sponsored-research staff to determine what the award permits and whether current NIH guidance or additional approval applies. They can raise award-specific questions with the NIH program officer and grants management specialist.
For any proposed source of temporary support, verify that the funds are actually available to the institution, that the study is eligible, and that the proposed expenses and timing are permitted. The NIH Office of AIDS Research describes HIV/AIDS research funding in relation to current scientific opportunities and research priorities: OAR HIV/AIDS funding overview. NHLBI describes expedited review for eligible HIV/AIDS-related applications, but expedited review is not a promise about when a particular award will be made and does not settle a delay on an existing award: NHLBI HIV/AIDS-related research FAQs.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Quick Recap
Best Value
Rank #4
Who to contact
- PI and study leadership: coordinate the operational review and identify time-sensitive participant and study needs.
- Institutional sponsored-research or grants office: clarify the delayed action, review award terms and current notices, and determine the approval route for proposed changes.
- IRB: assess proposed changes to approved human-subjects research and advise on required review or notification.
- Data and safety monitoring body: address study-specific safety oversight and monitoring implications.
- NIH program officer and grants management specialist: seek guidance on the award-specific scientific and administrative questions through the institution’s grants staff.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
